Historically, emergency preparedness programs in long-term care facilities have been less prioritized, with facilities understandably focusing on patient care and operations. 

But with the pandemic and President Biden’s nursing home reform plan, a focus on emergency preparedness is key, and facilities should concentrate on, and perfect, their emergency preparedness programs now.  And we don’t mean just on paper.

Historically, emergency preparedness programs in long-term care facilities have been less prioritized, with facilities understandably focusing on patient care and operations. 

But with the pandemic and President Biden’s nursing home reform plan, a focus on emergency preparedness is key, and facilities should concentrate on, and perfect, their emergency preparedness programs now.  And we don’t mean just on paper.

The Health & Life Sciences Section is pleased to announce it is offering a scholarship for the American Health Lawyers Association Fundamentals of Health Law Conference, November 9-11, 2022, in Chicago. 

The Health & Life Sciences Section is pleased to announce it is offering a scholarship for the American Health Lawyers Association Fundamentals of Health Law Conference, November 9-11, 2022, in Chicago. 

On June 15, 2022, after many years of ongoing litigation1, the U.S. Supreme Court unanimously overturned a substantial Medicare Part B payment reduction to many 340B Program participating hospitals related to certain outpatient prescription drugs provided to Medicare patients for fiscal years 2018 and 2019, totaling an estimated $1.6 billion across all affected entities.

On June 15, 2022, after many years of ongoing litigation1, the U.S. Supreme Court unanimously overturned a substantial Medicare Part B payment reduction to many 340B Program participating hospitals related to certain outpatient prescription drugs provided to Medicare patients for fiscal years 2018 and 2019, totaling an estimated $1.6 billion across all affected entities.

PhRMA, the pharmaceutical industry group, recently won a court order striking down the so-called "Patient Assistance Rule," which affects the Best Price pharmaceutical manufacturers must report to CMS for discounts under the Medicaid Drug Rebate Program and the 340B Drug Discount Program. The rule was meant to help curb the practice of "accumulator adjustment programs" used by insurance companies to divert pharmaceutical rebates from the patient to the insurer.

PhRMA, the pharmaceutical industry group, recently won a court order striking down the so-called "Patient Assistance Rule," which affects the Best Price pharmaceutical manufacturers must report to CMS for discounts under the Medicaid Drug Rebate Program and the 340B Drug Discount Program. The rule was meant to help curb the practice of "accumulator adjustment programs" used by insurance companies to divert pharmaceutical rebates from the patient to the insurer.